Abbreviation
Recombinant Human PTK7 protein, partial (Active)
Purity
Greater than 95% as determined by SDS-PAGE.
Greater than 95% as determined by SEC-HPLC.
Endotoxin
Less than 1.0 EU/ug as determined by LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human PTK7 at 2 μg/mL can bind Anti-PTK7 recombinant antibody (CSB-RA622651MA1HU). The EC50 is 0.3675 - 0.65842 ng/mL.
Alternative Names
Colon carcinoma kinase 4 (CCK-4); Protein-tyrosine kinase 7;Pseudo tyrosine kinase receptor 7; Tyrosine-protein kinase-like 7
Species
Homo sapiens (Human)
Expression Region
31-704aa
Target Protein Sequence
AIVFIKQPSSQDALQGRRALLRCEVEAPGPVHVYWLLDGAPVQDTERRFAQGSSLSFAAVDRLQDSGTFQCVARDDVTGEEARSANASFNIKWIEAGPVVLKHPASEAEIQPQTQVTLRCHIDGHPRPTYQWFRDGTPLSDGQSNHTVSSKERNLTLRPAGPEHSGLYSCCAHSAFGQACSSQNFTLSIADESFARVVLAPQDVVVARYEEAMFHCQFSAQPPPSLQWLFEDETPITNRSRPPHLRRATVFANGSLLLTQVRPRNAGIYRCIGQGQRGPPIILEATLHLAEIEDMPLFEPRVFTAGSEERVTCLPPKGLPEPSVWWEHAGVRLPTHGRVYQKGHELVLANIAESDAGVYTCHAANLAGQRRQDVNITVATVPSWLKKPQDSQLEEGKPGYLDCLTQATPKPTVVWYRNQMLISEDSRFEVFKNGTLRINSVEVYDGTWYRCMSSTPAGSIEAQARVQVLEKLKFTPPPQPQQCMEFDKEATVPCSATGREKPTIKWERADGSSLPEWVTDNAGTLHFARVTRDDAGNYTCIASNGPQGQIRAHVQLTVAVFITFKVEPERTTVYQGHTALLQCEAQGDPKPLIQWKGKDRILDPTKLGPRMHIFQNGSLVIHDVAPEDSGRYTCIAGNSCNIKHTEAPLYVVDKPVPEESEGPGSPPPYKMIQT
Note: The complete
sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is
translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application,
please explicitly request the full and complete sequence of this protein before ordering.
Tag Info
C-terminal 10xHis-tagged
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Buffer
Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4
Storage
Store at -20°C/-81°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Lead Time
3-7 business days
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Shelf Life
The shelf life is related to many factors, storage state, storage temperature and the stability of the product itself. Generally, the shelf life of lyophilized form is 6 months at -20°C/-80°C from the date of receipt.
Datasheet & COA
Please contact us to get it.
Images
-
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
-
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human PTK7 at 2 μg/ml can bind Anti-PTK7 recombinant antibody (CSB-RA622651MA1HU). The EC50 is 0.3675 - 0.65842 ng/mL.
-
The purity of PTK7 was greater than 95% as determined by SEC-HPLC
Description
PTK7 functions as a pseudokinase receptor implicated in Wnt signaling and cancer progression, yet its catalytically inactive kinase domain complicates the production of conformationally authentic extracellular fragments for antibody development and ligand discovery. This mammalian-expressed construct spanning residues 31–704 captures the complete extracellular region, preserving native glycosylation and disulfide architecture essential for antibody epitope presentation. Functional ELISA validation demonstrates specific binding to an anti-PTK7 recombinant antibody with an EC50 of 0.37–0.66 ng/mL, confirming that the protein adopts a conformation suitable for therapeutic antibody epitope mapping, blocking antibody screening, and competitive inhibition assays targeting PTK7-mediated oncogenic pathways. The protein meets purity thresholds exceeding 95% by SDS-PAGE and endotoxin levels below 1.0 EU/μg, aligning with standards expected in surface plasmon resonance affinity characterization and biolayer interferometry experiments for drug discovery programs focused on PTK7 as a cancer target.
